Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9479707 | 0.94 | PDE10A (0.46) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL16289622 | 0.93 | PDE10A (0.45) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL9480330 | 0.93 | PDE10A (0.45) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL16287758 | 0.93 | PDE10A (0.45) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL177540 | 0.88 | PDE10A (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL6798820 | 0.88 | CYSLTR2 (0.53) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL2334595 | 0.86 | CYSLTR2 (0.52) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL2913941 | 0.83 | PDE10A (0.61) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL8904769 | 0.81 | PDE10A (0.48) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL10518603 | 0.81 | CYSLTR1 (0.51) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39836-E1 | Macrolide antinfective agents | KOSAN BIOSCIENCES, INC. (US) | 2007-09-11 | — | — | US | claimed |
| US-6593302-B2 | Antibiotics | KOSAN BIOSCIENCES, INC. | 2003-07-15 | — | — | US | claimed |
| EP-2952096-B1 | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9814235-B2 | Method for controlling arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-2212328-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF | CHOONGWAE PHARMA CORP (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-2952096-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | Sumitomo Chemical Company, Limited (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2212330-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (3) | CHOONGWAE PHARMA CORP (KR) | 2015-04-08 | — | — | EP | disclosed |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-01 | — | — | US | disclosed |
| EP-2813492-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | Sumitomo Chemical Co., Ltd (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| CN-1151746-A | Novel erythromycin derivatives, process for their preparation and their use as medicaments | ROUSSEL UCLAF (FR) | 1997-06-11 | — | — | CN | disclosed |
| US-5606078-A | ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0678514-A1 | 3,5-Disubstituted tetrahydrofuran-2-ones | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5190957-A | TREATMENT OF MULTI-DRUG RESISTANT TUMORS WITH QUINOLYL-AND ISOQUINOLYLOXAZOLE-2-ONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-02 | — | — | US | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | H1-0, H1-3, H1-2 | PDE10A 2251/4885CYSLTR2 2017/4885CYSLTR1 2277/4885 |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | RPS8, MT-CO2, ARG1 | PDE10A 2449/4885CYSLTR2 1264/4885CYSLTR1 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.